High throughput design, synthesis and in vivo evaluation of targeted molecular im
High throughput design, synthesis and in vivo evaluation of targeted molecular im
批准号:
8047904
负责人:
JULIE L SUTCLIFFE
金额:
$352.0万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2013-09-29
关键词:
AddressAffinityAnimal ModelAnimalsAreaAutomationBiologicalBiological MarkersBiological PreservationChemical EngineeringCherry - dietaryComplexDataData CollectionData SetDevelopmentDiagnosisDiseaseEvaluationFundingGenomicsGoalsGrowthHalf-LifeImageImage AnalysisImageryImaging technologyIn VitroLibrariesMedicineMethodsMicrofabricationMicrofluidicsMolecularMolecular BankMolecular ProbesMolecular TargetMonitorOccupationsOrganPeptidesPerformancePositron-Emission TomographyPostdoctoral FellowProcessQiRadiolabeledRecoveryResearchResearch PersonnelRetrievalScreening procedureStagingStudentsTechniquesTechnologyTherapeuticTimeTraining SupportTranslationsbasebench to bedsidecombinatorialcombinatorial chemistrycostdata acquisitiondesignhigh throughput technologyimage reconstructionimaging Segmentationimaging probeimprovedin vivomolecular imagingmultidisciplinarynoveloncologyoutcome forecastpre-clinicalprocess optimizationprofessorradiotracerresponsetherapeutic targettreatment response
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): High throughput design, synthesis and in vivo evaluation of targeted molecular imaging agents. This is a 3-year proposal in response to the RFA-OD-10-005. This proposal addresses components of all 5 thematic areas with the closest association with the thematic area "Applying Genomics and other High throughput technologies". Molecular imaging, a noninvasive, quantitative visualization of in vivo molecular processes occurring at the cellular and sub cellular level is becoming an enabling technology for personalized medicine. Development of target specific molecular imaging agents is critical for the growth of this field. Current limitations for the rapid development of targeted molecular imaging agents include the complex design, synthesis and screening approaches for radiolabeled compounds, the short half-lives of the radiolabeled compounds, automation of the synthesis of radiolabeled compounds, rapid in vivo screening of the compounds and finally rapid automated analysis of the large data sets acquired. We are therefore proposing to address these limitations by developing a high-throughput platform that will streamline not only the in vitro selection but also the synthesis and in vivo evaluation of novel targeted molecular imaging agents. We will utilize the advances made in combinatorial chemistry, microfabrication, microfluidics and small animal imaging technologies to screen peptide based libraries designed as targeted molecular imaging agents for utilization with PET. We have assembled a multidisciplinary team of investigators Professors Sutcliffe (radiochemist), Cherry (PET physicist), Revzin (chemical engineer) and Qi (physicist/mathematician). In line with the purpose of the Recovery Act we are requesting funds for students and post doctoral fellows to support training in the field as well as technician support for Dave Kukis and Jennifer Fung (staff at CMGI) to enable job preservation. We believe that by focusing our efforts on high-throughput compound retrieval and in vivo screening our approach has the potential to minimize the need for extensive and time consuming in vitro analysis These advances in the development of molecular probes as targeted imaging biomarkers will significantly help to facilitate personalized medicine, improving our ability to detect, diagnose, stage, monitor and guide treatment response and determine prognosis in many diseases.
PUBLIC HEALTH RELEVANCE: Molecular imaging is a noninvasive, quantitative visualization of in vivo molecular processes occurring at the cellular and sub cellular level that is becoming an enabling technology for personalized medicine. We are proposing to accelerate the development of target specific molecular imaging agents. These advances in the development of molecular imaging agents as targeted imaging biomarkers will significantly help to facilitate personalized medicine, improving our ability to detect, diagnose, stage, monitor and guide treatment response and determine prognosis in many diseases.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/anie.201303965
发表时间:
2013-08-26
期刊:
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
影响因子:
16.6
作者:
[Siltanen, Christian, Shin, Dong-Sik, Sutcliffe, Julie, Revzin, Alexander]
通讯作者:
Revzin, Alexander
Establishment of clonal MIN-O transplant lines for molecular imaging via lentiviral transduction & in vitro culture.
通过慢病毒转导建立用于分子成像的克隆 MIN-O 移植系
DOI:
10.1371/journal.pone.0039350
发表时间:
2012
期刊:
PloS one
影响因子:
3.7
作者:
[Boucher,DavidL, Chen,JaneQian, Cherry,SimonR, Borowsky,AlexanderD]
通讯作者:
Borowsky,AlexanderD
Peptide-based targeted molecular imaging for early detection in pancreatic cancer
-
批准号:10224114
-
项目类别:
-
资助金额:$62.91万
-
财政年份:2017
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
Peptide-based targeted molecular imaging for early detection in pancreatic cancer
-
批准号:9752492
-
项目类别:
-
资助金额:$61.55万
-
财政年份:2017
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
avb6-directed molecular imaging and therapy
-
批准号:9187807
-
项目类别:
-
资助金额:$48.87万
-
财政年份:2015
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
An integrated radiopharmaceutical synthesis system
-
批准号:7390051
-
项目类别:
-
资助金额:$49.73万
-
财政年份:2008
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
Targeting of alpha v beta 6 integrin in oral cancer
-
批准号:6783658
-
项目类别:
-
资助金额:$16.31万
-
财政年份:2004
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
Targeting of alpha v beta 6 integrin in oral cancer
-
批准号:6902687
-
项目类别:
-
资助金额:$16.97万
-
财政年份:2004
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
Targeting of alpha v beta 6 integrin in oral cancer
-
批准号:7283144
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2004
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
Targeting of alpha v beta 6 integrin in oral cancer
-
批准号:7272331
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2004
-
负责人:JULIE L SUTCLIFFE
-
依托单位:
海外基金